Opportunity ID: 163193

General Information

Document Type:: Grants Notice
Funding Opportunity Number:: RFA-AI-12-018
Funding Opportunity Title:: Clinical Trials Units for NIAID Networks (UM1)
Opportunity Category:: Discretionary
Opportunity Category Explanation::
Funding Instrument Type::
Category of Funding Activity:: Health
Category Explanation::
Expected Number of Awards::
Assistance Listings Number(s):: 93.855 — Allergy, Immunology and Transplantation Research
Cost Sharing or Matching Requirement:: No
Version:: Synopsis 1
Posted Date:: Apr 10, 2012
Last Updated Date::
Original Closing Date for Applications:: Jan 29, 2013
Current Closing Date for Applications:: Jan 29, 2013
Archive Date:: Mar 01, 2013
Estimated Total Program Funding:: $ 70,000,000
Award Ceiling:: $
Award Floor:: $

Eligibility

Eligible Applicants:: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility:: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name:: National Institutes of Health
Description:: The purpose of this FOA is to solicit applications for Clinical Trials Units (CTUs) for NIAID clinical research networks focused on the following six research areas: 1) Adult HIV therapeutic strategies, including HIV cure, noninfectious comorbidities, and the infectious comorbidities of hepatitis and tuberculosis; 2) strategies to address HIV and HIV-associated infections in pediatric and maternal populations; 3) integrated HIV prevention strategies; 4) microbicide strategies to prevent HIV infections; 5) vaccines to prevent HIV infections; and 6) strategies to address antibacterial resistance.
Link to Additional Information::
Grantor Contact Information:: If you have difficulty accessing the full announcement electronically, please contact:

Version History

Version Modification Description Updated Date
Synopsis 1

Package Status

Package No: 1

Related Documents